Rankings
▼
Calendar
NVAX Q3 2023 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena
NVAX
Novavax, Inc.
$2B
Q3 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$22M
-97.0% YoY
Gross Profit
-$77M
-348.4% margin
Operating Income
-$126M
-569.4% margin
Net Income
-$131M
-592.7% margin
EPS (Diluted)
$-1.26
QoQ Revenue Growth
-94.8%
Cash Flow
Operating Cash Flow
-$40M
Free Cash Flow
-$58M
Stock-Based Comp.
$21M
Balance Sheet
Total Assets
$1.7B
Total Liabilities
$2.3B
Stockholders' Equity
-$678M
Cash & Equivalents
$651M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$22M
$735M
-97.0%
Gross Profit
-$77M
$300M
-125.6%
Operating Income
-$126M
-$127M
+1.2%
Net Income
-$131M
-$169M
+22.4%
Revenue Segments
Grant
$165M
88%
Royalties and Other
$20M
11%
Product
$2M
1%
Geographic Segments
North America
$2M
100%
← FY 2023
All Quarters
Q4 2023 →